RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

This real-world study (not an experiment — it observes what happens in routine clinical practice) tracks the effectiveness and safety of ribociclib, a drug used alongside hormone therapy, in Saudi Arabian patients with hormone receptor-positive, HER2-negative early-stage breast cancer after surgery. **You may be eligible if...** - You are 18 or older - You have been diagnosed with hormone receptor-positive (estrogen and/or progesterone receptor positive), HER2-negative early-stage breast cancer - Your cancer is stage IIA (a subset), IIB, or stage III - You are currently receiving ribociclib in combination with hormone therapy (adjuvant endocrine therapy) as part of your treatment plan, started within the past 6 months **You may NOT be eligible if...** - You have already started and stopped ribociclib for reasons other than study exclusion criteria - You have metastatic breast cancer - You have conditions that prevent participation per study guidelines Talk to your doctor to see if this trial is right for you.